The future of surgical management of inflammatory bowel disease

Diseases of the Colon and Rectum

Volumn 51, Issue 6, 2008, Pages 813-817

  Koltun, Walter A ^a,b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOTYPE; ENTERITIS; ENVIRONMENTAL EXPOSURE; GENETIC PREDISPOSITION; HUMAN; PHENOTYPE; REVIEW;

BIOMEDICAL RESEARCH; DIGESTIVE SYSTEM SURGICAL PROCEDURES; FORECASTING; HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 44749087317     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1007/s10350-008-9266-8     Document Type: Review

References (19)

1. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:559-603.
2. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-6.
3. Cho J. Genetic advances in inflammatory bowel disease. Curr Treat Options Gastroenterol 2006;9:191-200.
4. Parkes M, Barrett JC, Prescott NJ, et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Genet 2007;39:830-2.
5. Goyette P, Labbe C, Trinh TT, et al. Molecular pathogenesis of inflammatory bowel disease: genotypes, phenotypes and personalized medicine. Ann Med 2007;39:177-99.
6. Kucharzik T, Maaser C, Lugering A, et al. Recent understanding of IBD pathogenesis: implications for future therapies. Inflamm Bowel Dis 2006;12:1068-3.
7. Summers RW. Novel and future medical management of inflammatory bowel disease. Surg Clin North Am 2007;87:727-41.
8. Thorlacius H, Toth E. Role of chromoendoscopy in colon cancer surveillance in inflammatory bowel disease. Inflamm Bowel Dis 2007;13:911-7.
9. Jones SL, Loftus EV Jr. Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment. Inflamm Bowel Dis 2007;13:1299-307.
10. Rosh JR, Gross T, Mamula P, et al. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale. Inflamm Bowel Dis 2007;13:1024-30.
11. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85.
12. Poritz LS, Thompson J, Dowell A, et al. Increased presence of NOD2 mutations in patients with pouchitis after ileal pouch anal anastomosis (IPAA) for ulcerative colitis (UC). Dis Colon Rectum 2006;49:739.
13. Meier CB, Hegazi RA, Aisenberg J, et al. Innate immune receptor genetic polymorphisms in pouchitis: is CARD15 a susceptibility factor. Inflamm Bowel Dis 2005;11:965-71.
14. Poritz LS, Koltun WA. Techniques of disease activity assessment in Crohn's disease. Semin Colon Rectal Surg 2001;12:16-21.
15. Langhorst J, Elsenbruch S, Koelzer J, et al. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008;103:162-9.
16. Targan SR. The utility of ANCA and ASCA in inflammatory bowel disease. Inflamm Bowel Dis 1999;5:61-3.
17. MacDermott RP. Lack of current clinical value of serological testing in the evaluation of patients with IBD. Inflamm Bowel Dis 1999;5:64-5.
18. Present DH, Banks PA. Section editors' commentary. The role of pANCA and ASCA in differentiating ulcerative colitis, Crohn's disease, and indeterminate colitis. Inflamm Bowel Dis 1999;5:66-7.
19. Haluck RS, Koltun WA eds. Imaging and robotics in surgical practice. Operative Techniques in General Surgery. Philadelphia: Elsevier, 2005;7.